Biovie Inc SEC Filings

BioVie Inc. reported results from its 2025 annual meeting of stockholders. On the September 22, 2025 record date, 7,535,080 shares were outstanding, and 3,417,857 shares were present for quorum. Stockholders elected all six director nominees to one‑year terms; each nominee received over 1.51 million "For" votes, with 1,864,509 broker non‑votes recorded on each director item.

Stockholders ratified EisnerAmper LLP as independent auditor for the fiscal year ending June 30, 2026 with 3,245,049 For, 141,868 Against, and 30,940 Abstain. They also approved an amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance to 3,100,000 (votes: 1,340,062 For, 207,794 Against, 5,492 Abstain, and 1,864,509 broker non‑votes).

BioVie Inc. filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $5.1 million, driven by operating expenses of $5.3 million (R&D $2.9 million; G&A $2.3 million). Other income, net, was $0.2 million mainly from interest income.

Cash and cash equivalents rose to $25.0 million from $17.5 million at June 30, 2025, supported by net proceeds of approximately $10.5 million from an August 2025 underwritten offering of units and pre-funded units, each including warrants exercisable at $2.50. Net cash used in operations was $3.0 million.

The company advanced its clinical programs: a Phase 2b study in Parkinson’s disease commenced in April 2025, and the DOD-funded Long COVID Phase 2 study continued, with $336,000 in grant reimbursements recognized this quarter. BioVie disclosed “substantial doubt” about its ability to continue as a going concern, noting dependence on additional financing. A 1-for-10 reverse stock split became effective July 7, 2025. Shares outstanding were 7,540,316 as of November 7, 2025.

BioVie Inc. (BIVI) filed a Form 3, the initial statement of beneficial ownership for a board member. The reporting person is a Director, and the filing states that no securities are beneficially owned as of the event date 07/17/2025. The form indicates it was filed by one reporting person. This is a routine ownership disclosure that establishes the insider’s baseline holdings at the time of becoming subject to reporting.

BioVie Inc. (BIVI) disclosed a Form 3 filed by a director, indicating no securities are beneficially owned by the reporting person. The filing identifies the relationship as Director and notes the event date as 07/17/2025. The form was filed by one reporting person.

BioVie Inc. solicits shareholder votes at its virtual annual meeting and presents director nominees, auditor ratification and an amendment to increase shares available under its 2019 equity plan to 3,100,000 shares. The proxy names the board slate including Cuong Do (President & CEO) and committee chairs for audit, compensation and governance. Compensation tables show named executive officer pay components: for example, the CEO's total compensation entries include cash and equity components (reported totals such as $777,082 for one year and $420,621 for another row). Director and NEO equity holdings and outstanding option/RSU schedules are disclosed, including a listed beneficial ownership aggregate of 65,312 shares (0.9%) for listed insiders. Audit fees paid to the auditor are disclosed (audit-related fees shown as $99,750 and tax fees $26,250).

BioVie, Inc. (BIVI) is a development-stage biopharmaceutical company with no products approved for commercial sale and no revenues expected in the foreseeable future. The company reported approximately $17.5 million in cash and cash equivalents, stockholders' equity of about $19.0 million, and an accumulated deficit of approximately $352.1 million. For the year, reported net losses included $(17,911,585) and $(33,006,956) as referenced in the statements, with net loss per common share of $(12.12) for the most recent period on a weighted average of 1,477,372 shares. BioVie continues preclinical and clinical development activities, holds multiple issued and pending patents and patent applications, and lists significant operational risks including dependence on third-party contractors, need for additional capital, litigation, manufacturing and regulatory hurdles, and potential volatility and dilution from equity financings. Recent equity raises and warrant offerings are described, and management discloses lease, debt, and fair-value measurement items that affected financing costs and interest expense.

Cuong V Do, President & CEO and director of BioVie, purchased securities in the company's public offering. On 08/07/2025 he acquired 5,000 shares of common stock and received accompanying warrants covering 5,000 shares; the combined purchase price per share and warrant was $2.00 in connection with the offering that closed on 08/11/2025.

After the reported transactions the filing shows the reporting person beneficially owning 9,992 common shares and 5,050 warrants indirectly. The securities are held in the name of Do & Rickles Investments LLC.

BioVie Inc. completed a registered offering that generated approximately $10.4 million in net proceeds. The company sold 5,620,000 Units and 380,000 Pre-Funded Units, with each Unit containing one share of common stock and one warrant. Units were sold at $2.00 each and Pre-Funded Units at $1.999 each (reflecting a nominal $0.0001 exercise price for the Pre-Funded Warrants).

The Warrants began trading on The Nasdaq Capital Market under the symbol BIVIW on August 8, 2025; each Warrant is immediately exercisable for one share at an exercise price of $2.50 and expires five years from issuance. The Underwriter, ThinkEquity LLC, exercised part of its over-allotment and purchased 667,300 Warrants for nominal additional proceeds; it received 300,000 Underwriter's Warrants exercisable at $2.50 and containing registration and anti-dilution rights. The offering closed August 11, 2025, proceeds are for working capital and general corporate purposes, and the Company and its officers and directors agreed to a three-month lock-up.